| abstract |
Compositions of lipophilic agents with improved solubility and stability can be provided. For example, a non-aqueous composition may be provided comprising a lipophilic agent and an amphiphilic polymerization solvent such as PEG400 but substantially free of organic solvents and insoluble particles. The composition may be further diluted with a desired aqueous diluent, such as an infusion solution, for parenteral administration to a subject (eg, a human). The composition can be used to treat those diseases or conditions sensitive to lipophilic agents, such as infectious diseases, malignancies or autoimmune diseases. |